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Abstract
Objectives: To evaluate the efficacy of Oraqix® during scaling and root planing (SRP) in comparison with 20% 
benzocaine and placebo.
Study Design: 15 patients requiring 4 sessions of SRP were enrolled. For each patient, Oraqix®, Hurricaine®, 
vaseline or no anesthetic product were randomly assigned each to a quadrant. Treatment pain was evaluated on a 
100 mm Visual Analog Scale (VAS) and on a Verbal Rating Scale (VRS). The amount of product administered, 
the need to re-anesthetise, patient and operator satisfaction and the onset of side-effects were also recorded.
Results: Oraqix® was significantly better than nothing, with a reduction of VAS score to 13.3 units, but without 
significant differences with Vaseline or Hurricaine®. Oraqix® was better in VRS reduction than not using any 
anesthetic (p=0.001) or using vaseline (p=0.024), but similar to Hurricaine®  (p=0.232). 
Conclusions: Oraqix® effectively controls pain in SRP procedures, with few side-effects and a good acceptance 
on the part of patients and clinicians.
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Introduction
It is estimated that about 52% of North American adult 
population is at risk of developing periodontal disease 
(1). Japan and Germany show similar prevalences. 
Treatment of this disease often includes Scaling and 
Root Planing (SRP), which is experienced by a signifi-
cant number of patients as painful and uncomfortable. 
(2-4). Thus, local anesthesia is often required (40%) (5). 
The main anesthetic techniques used are nerve block/
infiltration anesthesia either alone or in combination 
with topical anesthesia (6-9). 
Nevertheless, more than 25% of adults are afraid of in-
jections (10). Furthermore, the prolonged duration of 
the injected local anesthetic action and the sensation of 
tingling or numbness (mainly in lips and tongue) redu-
ces the tolerance of SRP carried out under conventional 
local anesthetics (6,7,10). 
Occasionally, topical anesthetics are used in order to 
reduce pain and discomfort during surgical procedures 
(6,9). The topical anesthetics most commonly used are 
20% benzocaine dental gel and 5% lidocaine spray (11). 
These methods have the drawback of incomplete adhe-
sion to the areas being treated. Thus, the topical anes-
thetic is washed away by saliva and part of its effect is 
lost. Other disadvantages of topical anesthetics are the 
lack of efficacy due to the insufficient ability to flow 
towards the deepest portion of the periodontal pocket, 
as well as the short duration of anesthesia, unfavour-
able taste and difficult application inside the periodontal 
pocket (6,9,12). 
For all the above mentioned reasons, an effective topical 
anesthetic ideally should be easy to apply, with painless 
administration and effective for any patient who is re-
luctant to receive injections (7,13). 
Oraqix® (Dentsply, Konstanz, Germany) is a topical 
anesthetic agent used in periodontal treatments for pain 
control. It consists of an eutectic mixture of 5% lidocaine 
and prilocaine (each gram contains 25-mg lidocaine and 
25-mg prilocaine) (6,7,14). To the mixture of anesthe-
tics, which already existed in the pharmaceutical market 
with the brand name EMLA® (15,16) (Eutectic Mixture 
of Local Anesthetics, AstraZeneca, Sodertalje, Sweden) 
thermosetting agents have been added, which make the 
consistency of the mixture vary from liquid to gel when 
temperature rises. Therefore, the anesthetic material is 
liquid at room temperature and turns into a gel at body 
temperature. Thus, by applying the anesthetic solution 
on the oral mucosa (with no perforation) and more spe-
cifically on the gingival pockets, Oraqix® consistency 
varies once administered, enabling it to remain in place 
(6-8,17) Oraqix® is supplied in dental cartridges that 
contain 1.7 g gel.; the anesthetic is applied on the gingi-
val margin around the teeth using a 23-G blunt-tipped 
applicator included in the package, which is similar to 
intraligament local anesthetic injections (11).
Different studies carried out with Oraqix® ( Donald-
son et al. (7), Jeffcoat et al. (13), Manner et al. (18) have 
evaluated its efficacy for intraoperative pain control 
during SRPs. However no study has so far compared 
the efficacy of Oraqix® with 20% benzocaine used in 
periodontal treatments.
Therefore, the objective of this split-mouth, double-
blind, randomised controlled clinical trial was to deter-
mine the efficacy of Oraqix® during the SRP proce-
dure and to compare this anesthetic material with 20% 
benzocaine and placebo. The secondary aims were to 
assess the amount of local anesthetic administered and 
product reapplication, to evaluate post-treatment pain 
using a Visual Analog Scale (VAS) and a Verbal Rating 
Scale (VRS), to assess patient and operator satisfaction 
and finally, to determine possible adverse affects.
Material and Methods
A randomised double-blind clinical trial controlled with 
a placebo was conducted between from January 2008 to 
January 2009. The protocol of the study was approved 
by the CREC (Clinical Research Ethics Committee) of 
the School of Dentistry of the University of Barcelona, 
Spain. All included patients needed periodontal treat-
ment in 4 quadrants. Each patient had its 4 quadrants 
randomly assigned to one of the following 4 options 
for anesthetic method: topical anesthetic with Oraqix® 
(Dentsply, Konstanz, Germany), topical anesthetic with 
Hurricaine® (Clarben, Madrid, Spain), Vaseline cream 
(Vaselina Cusí®, Sanofi-Synthelabo, Barcelona, Spain) 
and no anesthetic method. Thus, all patients received the 
4 treatment modalities. The sample size was calculated 
using the statistics program G*Power 3.0 (19) and re-
peated-measures ANOVA design was also used. A VAS 
variance as reported for anesthetics was 3 and for inter-
group variance was 14. Errors were set at α=0.05 and 
β=0.2. A total of 12 patients met the inclusion criteria 
and total sample size was determined to be 15 patients 
in total, in order to compensate possible dropouts.
Fifteen patients visiting the Pathology and Surgery Pe-
riodontal Unit of the Master’s Degree Program in Oral 
Surgery and Implantology (School of Dentistry, Uni-
versity of Barcelona, Barcelona, Spain) were included 
in the study. All participants met the inclusion criteria 
(Table 1) and written informed consent was obtained in 
order to participate in the clinical trial. 
All SRPs were carried out by 3 third-year fellows of the 
Master’s Degree Program in Oral Surgery and Implan-
tology of University of Barcelona during four sessions, 
separated by 1 week. All patients were seen by the same 
operator to eliminate interexaminer variability.
Each patient was selected at random by means of a draw 
in each of the quadrants in order to identify the type of 
treatment to be used ( Oraqix®, Hurricaine®, Vaselina 
Cusí®, or no anesthetic product). The randomised treat-
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Inclusion Criteria Exclusion Criteria
Over 18 years old.•	
Minimum 5 teeth per quadrant, of which at least 3 •	
have periodontal pockets at least 5 mm deep and 
requiring SRP.
Patients with history of sensibility to probing or •	
discomfort in previous SRPs.
Capacity to understand VAS (visual analog scale to •	
assess pain).
Signed informed consent.•	
History of allergy, hypersensibility or any other •	
type of reaction to local anesthetics of the group of 
amides.
Record of metahemoglobinemia.•	
Taken analgesics, anesthetics, sedatives and/or anxi-•	
olytics in the last 12 hours prior to the SRP.
Recent SRP of the quadrant to be studied (in the last •	
12 months).
Pregnancy or breastfeeding.•	
Heart, kidney or liver disease.•	
Has previously participated in the same study.•	
Active infection in the tooth to be treated or in its •	
surroundings.
Wounds, necrotic ulcers in the marginal gums.•	
Table 1. Inclusion and exclusion criteria of study participants.
Fig. 1. Application of Oraqix® inside the periodontal pocket.
ment sequence was assigned to each patient before se-
lection. The selected sequence was reported to the cli-
nician that was in charge of each anesthetic technique 
prior to application.
A different operator to the one who perform the SRP, 
anesthetised the quadrant with the specific product as-
signed to it after probing each tooth of the chosen qua-
drant at 6 points and recording whether there was any 
bleeding or wound suppuration. Thus, the teeth were 
isolated with cotton rolls or lip separators and the se-
lected product was placed inside the periodontal pockets 
from distal to mesial side. Oraqix® was introduced in-
side the periodontal pocket using an applicator designed 
for such purpose (Fig. 1). In contrast, Hurricaine® (20% 
benzocaine dental gel) was applied with a cotton swab 
and subsequently introduced into the periodontal po-
cket using a probe. The same procedure was chosen for 
vaseline, and finally, in those quadrants where no anes-
thetic product was selected, the periodontal probe was 
only passed through the gingival margins with the aim 
of masking the treatment.
Following a waiting period of 30 to 45 seconds, a second 
operator started the instrumentation using universal and 
specific curettes from distal side to the half-way line. 
When reanesthesia was needed, the first operator placed 
more product on the painful area without the presence of 
a second operator so as not to loose the masking effect. 
After 30 seconds, the second operator entered the oper-
ating theatre and continued with the SRP procedure. In 
those areas that were not anesthetised, the same opera-
tor who had performed the SRP infiltrated the operating 
side with 4% Articaine with 1:100.000 Epinephrine (In-
hibsa, Barcelona, Spain) as many times as needed. The 
amount of Oraqix® used was recorded. Patients were 
prescribed analgesic medication usually oral ibuprofen 
600 mg, 1 granulated sachet every 8 hours (Espidifen®, 
Zambon Group, Vicenza, Italy).
During immediate follow-up period, within 5 minutes 
after treatment, the patient had to answer the following 
question: How much pain did you feel during the SRP 
procedure? The answer was marked with a vertical line 
on a horizontal line of 100 mm (VAS); in the far left 
the painless situation was found whereas the far right 
of the line represented the highest degree of pain. The 
SRP pain was also assessed using a five-point VRS (No 
pain, slight pain, medium pain, severe pain or very se-
vere pain) that refers to the general degree of patient’s 
unpleasantness during the treatment. The taste of the 
anesthetic used was also recorded (Not unpleasant, un-
pleasant, and very unpleasant). The ease of product ap-
plication by the operator was also evaluated (very easy, 
easy, medium or difficult) as well as the possible altera-
tion in the operator’s sense of touch when using the cu-
rettes (none, some, quite or quite a lot). 
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All patients were given a questionnaire in order to iden-
tify the following adverse effects: stinging pain, irri-
tation, soreness, swelling, loss of feeling, alteration of 
taste, nausea, fatigue, cephalea at 24 and 48 hours. The 
questionnaire was collected after 7 days during follow 
up visit or before the next SRP procedure.
The SPSS Inc., Chicago, IL. USA, version 15.0 statisti-
cal package was used throughout the statistical analysis 
(license of the University of Barcelona). A repeated-
measures ANOVA design was also used for the VAS 
scores, the VRS scores, and the depth of the probe, in 
which intrasubject variability was compared across the 
anesthetic technique used and gender was considered 
a between-subjects variable. The analysis of categori-
cal variables was carried out by χ2 tests. Analysis was 
intention-to-treat.
  
Results
A total of 10 males and 5 females, aged 29-71, were in-
cluded in the study. The mean age of the participants 
was 51 years. Figure 2 describes the progress of partici-
pants through the different stages of the present study. 
All quadrants could be treated with the initially as-
signed substance. No statistical significant association 
for the VAS scores, the VRS scores and the postopera-
1
Evaluation of eligibility 
  (n=19) 
Excluded (n= 4) 
Did not meet the inclusion criteria (n=2) 
Refused to participate (n= 1) 
Other reasons (n=1) 
Analysed (n=15) 
Excluded from analysis 
Assigned at the intervention (n= 15) 
Received the assigned intervention
(n= 15) 
Did not receive the assigned 
intervention (n= 0) 
Randomised (n=15) 
Analysed (n=15) 
Excluded from analysis 
Analysed (n=15) 
Excluded from analysis 
Analysed (n=15) 
Excluded from analysis 
Assigned at the intervention (n= 15) 
Received the assigned intervention
(n= 15) 
Did not receive the assigned 
intervention (n= 0) 
Assigned at the intervention (n= 15) 
Received the assigned intervention
(n= 15) 
Did not receive the assigned 
intervention (n= 0) 
Assigned at the intervention (n= 15) 
Received the assigned intervention
(n= 15) 
Did not receive the assigned 
intervention (n= 0) 
Fig. 2. Flow chart of subjects throughout the stages of the study. There were no follow-up dropouts. 
tive complications reported at 24 and 48 hours with age 
and gender was observed.
-Probe depth: 
No statistical significant differences were observed in 
terms of probe depth between the 4 quadrants for each 
patient, nor even between different participants. Table 2 
shows probe depth measurements per quadrant for the 
15 patients included in the study.
-VAS: 
With respect to the VAS scores, differences between 
groups were not significant, although they came very 
close to the statistical significance value (F=0.513; df= 
3; p=0.053). Oraqix® proved to be significantly bet-
ter than not having anything, with a reduction of 13.3 
units of VAS (IC95 %: -25,6 a -3.0). Similar results were 
though found with Hurricaine®. There were no signifi-
cant gender differences (F=0.542, df=1, p=0.475) nor in-
teraction between gender and anesthetic type (F=0.151, 
df=3, p=0.927) as shown in figure 3.
-VRS: 
In the VRS analysis, some statistically significant dif-
ferences between groups (F=10.216, df=3; p= 4.26•10-5) 
were reported. Oraqix® proved better than not using 
any anesthetic method (p=0.001), with a reduction of 
1.2 points (IC 95 %: -1.8 a -0.6) and better than applying 
Med Oral Patol Oral Cir Bucal. 2014 Mar 1;19 (2):e192-201.                                                                                                                                                       RCT oraqix vs hurricaine and placebo
e196
Quadrant 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1st 3.7 3.3 4.8 3.8 3.8 4 4.2 5 4 3.1 3.8 3.5 4.1 4 3.8
2nd 3.9 3.3 4.8 3.8 3.6 4.2 4.3 4.9 4.1 3.4 4 3.38 4 3.8 3.6
3rd 3.3 3.1 4.9 4.2 3.71 3.9 3.8 4.6 3.8 3 3.7 3.43 3.8 3.9 3.4
4th 3.4 3.3 4.6 3.9 3.9 3.7 4.2 4.4 3.8 2.9 3.7 3.29 3.7 3.7 3.4
Table 2. Mean probing depth measures in mm of the quadrants for the 15 patients included in the study. Each column represents a 
patient. 
Fig. 3. VAS scores according to type of anesthetic administered and patient’s sex.
vaseline (p=0.024), with a reduction of 0.6 points (IC 
95 %: -1,1 a -0,1), but it was similar to applying Hur-
ricaine®  (p=0.232; IC 95 %: -0.6 to 0.2). There were no 
differences in gender (F=0,117, df=1, p=0,738) nor in-
teraction between gender and anesthetic type (F=0.151, 
df=3, p=0.927). Figure 4 summarizes these results.
-Adverse effects:
Six patients treated with Oraqix® presented irritation 
or stinging pain at 24 hours following treatment, but 
it disappeared completely at 48 hour, except for one 
case. Four cases where no aesthetic material was ad-
ministered, 4 of those treated with Hurricaine® and 3 
of those who were applied Vaseline reported irritation 
at 24 hours. In one of the cases treated with Vaseline 
the irritation persisted for more than 48 hours. Only 
one patient reported alteration of sense of taste after 
the four treatment sessions, which disappeared at 48 
hours.
-Amount of product administered and need to re-anes-
thetise:
The average dosage of Oraqix® used was ¾ to 1 car-
tridge per quadrant.
3 patients needed Oraqix® reapplication; after this 
second administration, an infiltration anesthesia was 
needed for just one case. In the case of Hurricaine®, re-
application was necessary in 4 cases and in 2 of them it 
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Fig. 4. VRS scores, general degree of patient discomfort during the treatment (0= no pain, 1= slight pain, 2= medium pain, 3= severe pain, 
4= very severe pain) according to topical anesthetic administered and sex.
Anesthetic Reapplication of 
product
Infiltration 
anesthesia
Oraqix® 3/15 (20%) 1/15 (6.6%)
Hurricaine® 4/15 (26.7%) 2/15 (13.3%)
Vaselina Cusí ® 5/15 (33.3%) 5/15 (33.3%)
No product 7/15 (46.6%) 7/15 (46.6%)
Table 3. Patients who needed reapplication of anesthetic and injected 
anesthesia.  
was also necessary to administer infiltration anesthesia. 
Table 3 shows the results of this section. 
-Taste:
Five out of 15 patients reported an unpleasant taste when 
being anesthetised with Hurricaine® in contrast with 2 out 
of 15, who noticed an unpleasant taste after the topical a-
nesthetic with Oraqix®. For both topical anesthetics, there 
was only one case that referred a very unpleasant taste. 
When no anesthesia was applied or just vaseline was used, 
all patients claimed that the taste was not unpleasant.
All patients considered that the taste would not influ-
ence their choice in future applications of these topical 
anesthetics during SRP maintenance. The patient who 
reported a very unpleasant taste with Hurricaine®, said 
that he would be “somewhat influenced” on being treat-
ed with this product again. 
Ease of application and alteration in the operator’s sense 
of touch when using the curette:
Tables 4 and 5 show the results obtained regarding the 
ease of application and the alteration of the sense of 
touch when using the curettes. 
Discussion
In this study, the use of Oraqix® was associated with 
less intraoperative pain compared with the placebo. 
However no differences between the use of this anes-
thetic method and a 20% benzocaine dental gel were 
reported.
Previous studies published after the market introduc-
tion of Oraqix® have proved the efficacy of the mixture 
of 5% lidocaine and prilocaine (EMLA®). This topical 
anesthetic has been mainly used to achieve pain control 
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Anesthetic Very easy application Easy application Some difficulty of application
Oraqix® 9 (60%) 6 (40%) -
Hurricaine® - 12 (80%) 3 (20%)
Anesthetic No influence Some tactile 
alteration 
Oraqix® 13 (87%) 2 (13%)
Hurricaine®   7  (47%) 8 (53%) 
Table 4. Ease of product application  perceived by the clinician. 
Table 5. Alteration of curette touch perceived by the clinician dur-
ing SRP.
during sharp debridement of chronic leg ulcers of arte-
rial, venous or arteriovenous aetiology in Dermatology 
as well as for soft tissues anesthesia in children (20-22). 
However, the effective duration of the topical anesthetic 
finished at 60 minutes (23).
In Oral Surgery, EMLA® improves transepithelial 
transport compared with conventional topical anesthe-
tics (24). McMillan et al. evaluated he efficacy of this an-
esthetic into the oral cavity (25). These authors warned 
the viscosity of this topical anesthesia made necessary 
the use of a matrix in the oral mucosa for wound therapy. 
Furthermore, EMLA® cream can be difficult to deliver 
to the oral mucosa, and 20% benzocaine gel has shown 
greater efficacy (26). Additionally, Magnusson et al. 
(27) observed that EMLA® was a more effective topical 
anaesthetic than 5% lidocaine gel, although its duration 
of action is relatively short for operations on the gingiva 
(around 20 minutes). In Odontopediatrics EMLA® has 
been used to perform minor surgeries, such as primary 
tooth extractions (28).
In addition, a greater efficacy of EMLA® compared with 
20% benzocaine has been found in oral surgery for chil-
dren. The application of EMLA® in children reduced the 
pain of palatal injections and placement of rubber dam 
clamps (15,16). Abu Al-Melh et al. (12,29) concluded that 
topical agents based on a combination of 2.5% lidocaine 
and 2.5% prilocaine have shown promising results for 
anesthetic infiltration, as 20% benzocaine is not potent 
enough to eliminate pain from a needle prick.
The first studies referring to Oraqix® in scientific li-
terature appeared in 2001. Friskopp et al. (6) conducted 
a study to determine anesthetic onset and duration of 
Oraqix® for SRP. Thirty patients were randomised to 
30 seconds of treatment with Oraqix®. The gel was 
applied to periodontal pockets. Oraqix® provided a-
nesthesia after an application time of 30 seconds, with 
a mean duration of action of about 17 to 20 min. For 
this reason, in our study the waiting period was 30-45 
seconds after anesthetic application.
Friskopp and Huledal (14) described the plasma profiles 
of lidocaine and prilocaine following a single dose of 
Oraqix®  to patients undergoing SRP. The total dose 
applied per patient was 0.9 to 3.5 g. Peak plasma con-
centrations of lidocaine (99–266 ng/ml) and prilocaine 
(46–118 ng/ml) occurred 20–40 min after the start of 
application.
These levels were low compared to those reported to 
cause initial signs of toxicity (5000–l 6000 ng/ml). Side-
effects were few and mild local effects of short duration. 
The authors concluded that there is a large safety margin 
with respect to systemic effects following the application 
of 0.9 g to 3.5 g Oraqix® (maximum 2 cartridges) (14).
Besides, the use of an increased dose of 8.5 g Oraqix (5 
cartridges approximately) was well tolerated and dis-
played a wide safety margin with respect to plasma levels 
normally associated with systemic toxicity (17).
Three other multicenter studies analysed, together with 
our study, the efficacy of Oraqix® versus placebo as a 
topical anesthetic used in SRPs (Table 6). 
In conclusion, these three multicenter studies, showed 
that the application of Oraqix® in periodontal pockets 
is well tolerated by patients and it is more effective than 
the placebo in reducing pain during SRP. The anesthetic 
gel reduced the pain by at least 50%. The median dose 
of active gel administered was 1 cartridge per quadrant 
(range from three quarters of a cartridge to 2 cartridges) 
(7,13,18).
The innovation of the present study lies in the fact that 
Oraqix® was compared to another topical anesthetic and 
vaseline administration. In addition, the “split-mouth” 
design (with intrasubject measures) reduced possible 
variability. Furthermore, as this was not a multicenter 
study, the variability caused by different treatment pro-
tocols and clinicians involved is reduced. Therefore, the 
sample size is considerably decreased. A problem con-
nected with other trials is that concealment of treatment 
can be difficult, as placebo causes no numbness. 
In a multicenter study, Van Abu Al-Melh et al. (30) as-
sessed patients’ preference for Oraqix® versus injection 
anesthesia using 2% lidocaine. A total of 157 patients re-
porting fear to injections and requiring SRP procedure 
were included in the study. Two visits were randomly 
scheduled: at the first visit, the quadrant was anesthe-
tised with Oraqix® whereas 2% lidocaine was applied 
prior to the periodontal treatment. One hundred ten out 
of the 157 patients (70%) reported a preference for Ora-
qix®  due to less numbness following the procedure. 
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Thirty-five patients (22%) preferred the injection of 2% 
lidocaine as they indicated less pain and other discom-
forts during SRP, and 8 patients (12%) did not express a 
preference. Ninety-six percent of patients reported that 
anesthesia efficacy was better with injective anesthesia 
compared to 80% for the gel. The researcher’s opinion 
on the efficacy of both anesthetic technique was simi-
lar: 100% with lidocaine versus 76% with Oraqix®. Fi-
nally, of these patients 45% would be willing to return 
and use the same gel. In this study, with the limitation 
of a smaller sample size, a greater efficacy of Oraqix® 
was observed as 80% of the patients and professionals 
expressed satisfaction with this satisfactory anesthesia 
with the gel. Of the 3 unsatisfied patients, with just the 
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reapplication of Oraqix® the pain could be eased for 2 
of them. In the other patient the infiltration technique 
had to be resorted to. Specifically, this patient required 
administration of local anesthetic in all 4 sessions of 
SRP, which suggests that topical anesthesia was not ap-
propriate for this patient. We have only found one pre-
liminary study conducted by Faul et al. (31) concerning 
the use of benzocaine as topical anesthetic during SRP 
procedure. The purpose of this randomised, split-mouth 
study conducted in 21 patients was to compare the anal-
gesic efficacy between an intra-pocket topical 20% ben-
zocaine gel with a blunt-tip applicator (Ultracare®, Ul-
tradent Products Inc., South Jordan, Utah, U.S.A.) with 
conventional injection. Greater intra-operatorive pain 
was associated with the use of the gel in comparison to 
the conventional anesthetic, but 52% preferred topical 
over injected anaesthetic. In our study, 2 patients treated 
with Hurricaine® needed to receive anesthesia infiltra-
tion, however VAS and VRS scores obtained were simi-
lar to those obtained with Oraqix®.
In the aforementioned studies (7,13,18,30) and this pre-
set study, the possible adverse effects arising in the 
different groups of patients were also assessed: those 
treated with Oraqix®, with placebo and with lidocaine. 
In all cases the number of patients presenting transitory 
adverse effects was similar.
In conclusion, Oraqix® is an effective gel which redu-
ces the incidence of intraoperative pain during the SRP 
procedures, although there were no significant statisti-
cal differences compared with Hurricaine®. Patients 
treated with Oraqix® did not require another type of 
anesthetic. Slight unpleasant taste was reported by pa-
tients and ease of application by all operators. In 2 out 
of 15 cases the clinician felt a slight decrease in tactile 
perception when using curettes. 
Therefore, the application of Oraqix® is an effective 
technique for pain reduction during SRPs, reporting 
few side effects and a good acceptance on the part of 
both patients and clinics. Furthermore it is a useful a-
nesthetic method for individuals with dental anxiety 
and/or who are particularly sensitive to pain.
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